动态循环肿瘤DNA甲基化监测指导非转移性结直肠癌术后随访:前瞻性随机III期FIND试验
FIND试验将584例非转移性结直肠癌术后患者随机分为ctDNA甲基化引导监测组和标准CT监测组,中位随访23.3个月,两组复发率相似,但ctDNA引导组接受根治性意向治疗的比例显著更高(48.1%对23.6%),临床复发中位时间缩短3.9个月,肝肺局限性复发者根治性切除率更高。
要点
- ctDNA引导监测使复发后根治性意向治疗率从23.6%提升至48.1%。
- ctDNA引导组临床复发中位时间提前3.9个月,复发率无显著差异。
- 肝肺局限性复发者ctDNA引导组根治性切除率更高(42.3%对18.2%)。
核心结论
- ctDNA甲基化引导的动态监测通过更早发现可切除转移灶,提高非转移性结直肠癌术后复发患者的根治性意向治疗率。
- 长期生存获益尚待成熟数据进一步验证。
研究设计与样本
- FIND试验为前瞻性、多中心、随机III期研究(NCT05904665)。
- 非转移性结直肠癌术后患者随机分配至ctDNA引导监测组(289例)或标准CT监测组(295例),改良意向治疗人群共584例。
- ctDNA引导组阳性结果触发立即CT成像,阴性时继续双月CT和季度ctDNA检测,连续两次ctDNA阴性后恢复标准影像频率。
- 主要终点为复发患者接受根治性意向转移导向治疗的比例。
主要发现
- 中位随访23.3个月,两组复发率相似(18.0%对18.6%,P=.919)。
- ctDNA引导组根治性意向治疗率显著更高(48.1%对23.6%,相对风险2.03,P=.008)。
- ctDNA引导组临床复发中位时间显著缩短(9.5对13.4个月,P<.001), lead time为3.9个月。
- 肝和/或肺局限性复发者中,ctDNA引导组根治性切除率更高(42.3%对18.2%,P=.002)。
- 该组肝转移灶特征更有利:病灶≤3个者占75.0%对28.6%(P=.005),肿瘤大小≤3 cm者占90.0%对57.1%(P=.033),单叶病变者占80.0%对28.6%(P=.002)。
临床怎么用
- 对于非转移性结直肠癌术后患者,可考虑采用ctDNA甲基化动态监测联合影像学随访策略。
- ctDNA阳性时应及时行CT成像以评估可切除转移灶,争取根治性局部治疗机会。
局限性
- 长期生存获益尚未成熟,需等待后续分析验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that a dynamic surveillance strategy guided by circulating tumor DNA (ctDNA) methylation would increase the rate of curative-intent therapy for recurrence in patients with nonmetastatic colorectal cancer (CRC) after curative resection. METHODS: The FIND trial (ClinicalTrials.gov identifier: NCT05904665) is a prospective, multicenter, randomized, phase III study. Patients with nonmetastatic CRC were randomly assigned to ctDNA-guided surveillance or standard computed tomography (CT)-based monitoring. In the ctDNA-guided group, a positive ctDNA result triggered immediate CT imaging; if negative, bimonthly CT continued alongside quarterly ctDNA testing. After two consecutive ctDNA-negative results, imaging reverted to standard frequency. The primary end point was the proportion of patients with recurrence receiving curative-intent metastasis-directed therapy. RESULTS: Among 584 eligible patients (289 ctDNA-guided, 295 control) in the modified intention-to-treat population, with a median follow-up of 23.3 months, recurrence rates were similar (18.0% v 18.6%, P = .919). The ctDNA-guided group had a significantly higher rate of curative-intent treatment (48.1% v 23.6%, relative risk 2.03, P = .008). The median time to clinical recurrence was significantly shorter in the ctDNA-guided group than in the control group (9.5 v 13.4 months; P < .001), representing a lead time of 3.9 months. Among recurrences confined to the liver and/or lungs, the ctDNA-guided group showed higher curative resection rates (42.3% v 18.2%, P = .002). These patients had more favorable hepatic metastatic features: fewer lesions (≤3: 75.0% v 28.6%, P = .005), smaller tumor size (≤3 cm: 90.0% v 57.1%, P = .033), and more unilobar disease (80.0% v 28.6%, P = .002). CONCLUSION: ctDNA methylation-guided dynamic surveillance improves the rate of curative-intent therapy for recurrence in patients with initially nonmetastatic CRC through earlier detection of resectable metastases, pending validation of long-term survival benefit in future analyses with mature data.
引用
- Mo S, Zhou C, Ma M, et al. Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. J Clin Oncol. 2026. PMID: 42525894. doi:10.1200/JCO-25-03009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。